TGFB1 and melanoma: The PD effects were expected to translate to clinical signals such as tumor responses, because a neutralizing mAb with a lower affinity to all three TGF-β ligands (32,33) produced antitumor responses in patients with melanoma and renal cell carcinoma (RCC) at similar doses.